Hôpitaux Universitaires Henri Mondor, DMU Médecine, Service de Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris (AP-HP), 94010, Créteil, France.
IMRB, GRC CARMAS, Faculté de Santé de Créteil, Université Paris Est Créteil (UPEC), 94010, Créteil, France.
Crit Care. 2024 Apr 20;28(1):131. doi: 10.1186/s13054-024-04906-2.
Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) and requiring mechanical ventilation suffer from a high incidence of ventilator associated pneumonia (VAP), mainly related to Enterobacterales. Data regarding extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E) VAP are scarce. We aimed to investigate risk factors and outcomes of ESBL-E related VAP among critically ill coronavirus infectious disease-19 (COVID-19) patients who developed Enterobacterales related VAP.
We performed an ancillary analysis of a multicenter prospective international cohort study (COVID-ICU) that included 4929 COVID-19 critically ill patients. For the present analysis, only patients with complete data regarding resistance status of the first episode of Enterobacterales related VAP (ESBL-E and/or carbapenem-resistant Enterobacterales, CRE) and outcome were included.
We included 591 patients with Enterobacterales related VAP. The main causative species were Enterobacter sp (n = 224), E. coli (n = 111) and K. pneumoniae (n = 104). One hundred and fifteen patients (19%), developed a first ESBL-E related VAP, mostly related to Enterobacter sp (n = 40), K. pneumoniae (n = 36), and E. coli (n = 31). Eight patients (1%) developed CRE related VAP. In a multivariable analysis, African origin (North Africa or Sub-Saharan Africa) (OR 1.7 [1.07-2.71], p = 0.02), time between intubation and VAP (OR 1.06 [1.02-1.09], p = 0.002), PaO/FiO ratio on the day of VAP (OR 0.997 [0.994-0.999], p = 0.04) and trimethoprim-sulfamethoxazole exposure (OR 3.77 [1.15-12.4], p = 0.03) were associated with ESBL-E related VAP. Weaning from mechanical ventilation and mortality did not significantly differ between ESBL-E and non ESBL-E VAP.
ESBL-related VAP in COVID-19 critically-ill patients was not infrequent. Several risk factors were identified, among which some are modifiable and deserve further investigation. There was no impact of resistance of the first Enterobacterales related episode of VAP on outcome.
感染严重急性呼吸综合征冠状病毒 2 (SARS-COV 2) 并需要机械通气的患者发生呼吸机相关性肺炎 (VAP) 的发生率很高,主要与肠杆菌科有关。关于产超广谱β-内酰胺酶的肠杆菌科 (ESBL-E) VAP 的数据很少。我们旨在研究并发冠状病毒病 19 (COVID-19) 的危重病患者发生肠杆菌科相关 VAP 时,ESBL-E 相关 VAP 的危险因素和结局。
我们对包括 4929 例 COVID-19 危重病患者的多中心前瞻性国际队列研究 (COVID-ICU) 进行了辅助分析。本分析仅包括首次肠杆菌科相关 VAP(ESBL-E 和/或耐碳青霉烯肠杆菌科,CRE)耐药状态和结局完整数据的患者。
我们纳入了 591 例肠杆菌科相关 VAP 患者。主要致病物种为肠杆菌属(n=224)、大肠杆菌(n=111)和肺炎克雷伯菌(n=104)。115 名患者(19%)发生了首次 ESBL-E 相关 VAP,主要与肠杆菌属(n=40)、肺炎克雷伯菌(n=36)和大肠杆菌(n=31)有关。8 名患者(1%)发生了 CRE 相关 VAP。多变量分析显示,非洲血统(北非或撒哈拉以南非洲)(OR 1.7 [1.07-2.71],p=0.02)、插管与 VAP 之间的时间(OR 1.06 [1.02-1.09],p=0.002)、VAP 当天的 PaO/FiO 比值(OR 0.997 [0.994-0.999],p=0.04)和甲氧苄啶-磺胺甲恶唑暴露(OR 3.77 [1.15-12.4],p=0.03)与 ESBL-E 相关 VAP 相关。机械通气撤机和死亡率在 ESBL-E 和非 ESBL-E VAP 之间无显著差异。
COVID-19 危重病患者中 ESBL 相关 VAP 并不少见。确定了几个危险因素,其中一些是可以改变的,值得进一步研究。首次肠杆菌科相关 VAP 的耐药性对结局没有影响。